JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Faccone, D.
Right arrow Articles by Corso, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faccone, D.
Right arrow Articles by Corso, A.
Journal of Clinical Microbiology, November 2005, p. 5800-5803, Vol. 43, No. 11
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.11.5800-5803.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Emergence of a Streptococcus pneumoniae Clinical Isolate Highly Resistant to Telithromycin and Fluoroquinolones

Diego Faccone,1 Patricia Andres,1,2 Marcelo Galas,1 Marta Tokumoto,2 Adriana Rosato,3 and Alejandra Corso1*

Servicio Antimicrobianos, Dpto. Bacteriología, Instituto Nacional de Enfermedades Infecciosas-ANLIS "Dr. Carlos G. Malbrán," Buenos Aires, Argentina,1 Servicio de Microbiología, Intituto de Cardiología y Cirugía Cardiovascular Fundación Favaloro, Buenos Aires, Argentina,2 Division of Infectious Diseases, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia3

Received 8 July 2005/ Returned for modification 12 August 2005/ Accepted 31 August 2005

Streptococcus pneumoniae is a major pathogen causing community-acquired pneumonia and acute bronchitis. Macrolides, fluoroquinolones (FQs), and, recently, telithromycin (TEL) constitute primary therapeutic options, and rare cases of resistance have been reported. In this report, we describe the emergence of an S. pneumoniae clinical isolate with high-level TEL resistance (MIC, 256 µg/ml) and simultaneous resistance to FQs. Ongoing studies are oriented to elucidate the precise mechanism of resistance to TEL.


* Corresponding author. Mailing address: Servicio Antimicrobianos, INEI-ANLIS "Dr. Carlos G. Malbrán," Av. Velez Sarsfield 563 (1281), Buenos Aires, Argentina. Phone: 54-11-4303-2812. Fax: 54-11-4303-2812. E-mail: acorso{at}anlis.gov.ar.


Journal of Clinical Microbiology, November 2005, p. 5800-5803, Vol. 43, No. 11
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.11.5800-5803.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.